Healthcare diagnostics product supplier Bio-Rad Laboratories reported third-quarter revenue of $653 million, up 0.5% year-over-year. Despite beating analyst estimates, the stock fell over 3% following the earnings report. The company attributed slow growth to biotech funding challenges and academic research obstacles.

Bio-Rad’s adjusted net income rose 8% to nearly $61 million, with earnings per share at $2.26. The company maintained its 2025 guidance of revenue growth flat to 1% above 2024 results and an adjusted operating margin of 12% to 13%.

The Motley Fool Stock Advisor team did not include Bio-Rad Laboratories in their list of 10 best stocks for investors to buy now. The top 10 stocks selected by the team historically have generated significant returns, outperforming the S&P 500 by a wide margin.

Read more at Yahoo Finance: Why Bio-Rad Laboratories Stock Slipped by More Than 3% on Thursday